Replies to post #519703 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Woodford tried a hostile takeover likely to bring in a partner. The terms would not be as favorable years ago given the short attack and negative press against NWBO. Management didn't have a proven product, either.

We have since had the 2018 interim data, combination trial data, actual PIII data, manufacturing improvements, and many more patents. We are a few months away from UK approval. So management were 100% correct to resist attempts to take over the company as management now have near infinite leverage in negotiations.

If you care about maximizing shareholder value then you would commend management for the correct course of action they took throughout this process. No doubt Linda Powers' background at Latham and Watkins, her experience as legal council for the European Union, her work in George HW Bush's Commerce Department, which included drafting NAFTA, and her tenure at Georgetown teaching law, all provided her invaluable insight into how to best protect Northwest Biotherapeutics from nefarious interests seeking to undermine shareholders.

[LearningEveryTrade]

I think LP and team feels the better value and negotiation power comes with being closer to being a turn-key operation. I think we're pretty darn close.

Obviously, Woodford saw something good and wanted it before that turn-key operation could come to fruition. I was not here for the Woodford Fund self-destruct button pushing, so, I am not 100% on his motivations.

[biosectinvestor]

You don’t know what choices were available or if it was a reasonable offer, so saying that from this distance, without the information may make you feel better, but it’s not realistic. It’s likely a false assumption of what was available, and honestly, if you stayed invested despite not seeing it, it’s pure hindsight and hindsight is typically not useful, especially if it is not fully informed of the facts.